loading
Papers Papers/2022 Papers Papers/2022

Research.Publish.Connect.

Paper

Paper Unlock

Authors: Mukhammad Burhanudin ; Iswan Abbas Nusi ; Poernomo Boedi Setiawan ; Herry Purbayu ; Titong Sugihartono ; Ummi Maimunah ; Ulfa Kholili ; Budi Widodo ; Muhammad Miftahussurur ; Husin Thamrin and Amie Vidyani

Affiliation: Department of Internal Medicine, Faculty of medicine Universitas Airlangga, Dr. Soetomo General Hospital and Surabaya, Indonesia

Keyword(s): Portal hypertension, splanchnic vascular bed, pharmacological therapy, nonselective β-blocker, propranolol

Abstract: Portal hypertension is a clinical syndrome characterized by pathological elevation of portal venous pressure and all its consequences. In portal hypertension, there is an increase in pressure in the veins that carry blood from the splanchnic organs to the liver. The main factors of portal hypertension include increased intrahepatic resistance to portal blood flow due to degenerative nodules and increased splanchnic blood flow secondary to vasodilation in the splanchnic vascular bed. Clinical symptoms indicated in portal hypertension are varicella hemorrhage with hematemesis or vomiting of blood (vomitus may be red blood mixed with clumps or coffee grounds), and/or melena, i.e. red or black defecation-like petis (shrimp paste). The goal of treatment of patients with portal hypertension is to reduce portal pressure. Drugs for portal hypertension should be able to lower blood vessel portal pressure without lowering arterial pressure, which may aggravate hyperdynamic circulation and incr ease the risk of renal failure. Most of the drugs often used in clinical practice are splanchnic vascular vasoconstrictors vasopressin derivatives (terlipressin), somatostatin, somatostatin analogs (octreotide and vapreotide), Nonselective β-Blocker and Carvedilol. (More)

CC BY-NC-ND 4.0

Sign In Guest: Register as new SciTePress user now for free.

Sign In SciTePress user: please login.

PDF ImageMy Papers

You are not signed in, therefore limits apply to your IP address 3.133.128.227

In the current month:
Recent papers: 100 available of 100 total
2+ years older papers: 200 available of 200 total

Paper citation in several formats:
Burhanudin, M.; Nusi, I.; Setiawan, P.; Purbayu, H.; Sugihartono, T.; Maimunah, U.; Kholili, U.; Widodo, B.; Miftahussurur, M.; Thamrin, H. and Vidyani, A. (2018). Pharmacological Therapy of Portal Hypertension. In Proceedings of Surabaya International Physiology Seminar - SIPS; ISBN 978-989-758-340-7; ISSN 2184-3678, SciTePress, pages 389-396. DOI: 10.5220/0007339603890396

@conference{sips18,
author={Mukhammad Burhanudin. and Iswan Abbas Nusi. and Poernomo Boedi Setiawan. and Herry Purbayu. and Titong Sugihartono. and Ummi Maimunah. and Ulfa Kholili. and Budi Widodo. and Muhammad Miftahussurur. and Husin Thamrin. and Amie Vidyani.},
title={Pharmacological Therapy of Portal Hypertension},
booktitle={Proceedings of Surabaya International Physiology Seminar - SIPS},
year={2018},
pages={389-396},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0007339603890396},
isbn={978-989-758-340-7},
issn={2184-3678},
}

TY - CONF

JO - Proceedings of Surabaya International Physiology Seminar - SIPS
TI - Pharmacological Therapy of Portal Hypertension
SN - 978-989-758-340-7
IS - 2184-3678
AU - Burhanudin, M.
AU - Nusi, I.
AU - Setiawan, P.
AU - Purbayu, H.
AU - Sugihartono, T.
AU - Maimunah, U.
AU - Kholili, U.
AU - Widodo, B.
AU - Miftahussurur, M.
AU - Thamrin, H.
AU - Vidyani, A.
PY - 2018
SP - 389
EP - 396
DO - 10.5220/0007339603890396
PB - SciTePress